Arlington, VA & Reykjavik, Iceland — May 23, 2025 — Kerecis, the company pioneering the use of sustainably sourced fish skin in cellular therapy and tissue regeneration, today announced that Cigna, one of the largest health insurers in the United States, now includes Kerecis products in its medical coverage policy for the treatment of diabetic foot ulcers.
With this policy update, Kerecis fish skin grafts — including the MariGen® and Shield® product lines — became available to tens of millions of additional Americans. In total, nearly 200 million people in the United States are now covered under commercial insurance plans that recognize fish skin grafts as medically necessary for chronic wound care.
Cigna’s inclusion adds to the growing list of national and regional payers that support the clinical and economic value of intact fish skin for non-healing wounds. The coverage applies to patients whose diabetic foot ulcers have not adequately responded to conventional treatments and meets specified clinical criteria.
Access is a critical part of improving outcomes in chronic wound care. We are pleased that Cigna recognizes the clinical value of our technology and that more patients can now benefit from regenerative fish skin as part of their treatment options.
Fertram Sigurjonsson
– Founder and CEO of Kerecis.
